Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - A pilot study

Clinical Nephrology

Volumn 76, Issue 5, 2011, Pages 388-395

  Shavit, L ^a   Neykin, D ^a   Lifschitz, M ^a   Slotki, I ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Blood pressure; Eplerenone; Hemodialysis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANURIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MULTICENTER STUDY; OLIGURIA; OPEN STUDY; PILOT STUDY; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS; WEIGHT GAIN;

AGED; ALDOSTERONE ANTAGONISTS; ANURIA; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGURIA; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 82155196012     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106973     Document Type: Article

References (28)

1. Sealey JE, Laragh JH. Further studies of a natriuretic substance occurring in human urine and plasma. Circ Res. 1971; 28: 2, 32-43.
2. Edelman IS, Bogoroch R, Porter GA. On the mechanism of action of aldosterone on sodium transport. The role of protein synthesis. Proc Natl Acad Sci USA. 1963; 50: 1169-1177.
3. Lifschitz MD, Schrier RW, Edelman IS. Effect of actinomycin D on aldosterone-mediated changes in electrolyte excretion. Am J Physiol. 1973; 224: 376-380.
4. Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science. 1993; 259: 1132-1133.
5. Melby JC. Primary aldosteronism. Kidney Int. 1984; 26: 769-778.
6. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006; 2: 198-208, quiz, 1, 230.
7. Textor SC, Bakris GL. Treatment of Hypertension. Neph. Self-Assessment Program. ASN. 2006; 5: 311-323.
8. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006; 1: 940-951.
9. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16: 925-930.
10. Lifschitz MD. Hypertension in chronic renal failure. In: Brenner BM and Stein JH (eds). Contemporary Issues in Nephrology, Vol. 8. New York, NY: Churchill Livingstone; 1981. p. 223-246.
11. Lifschitz MD, Kirschenbaum MA, Rosenblatt SG, Gibney R. Effect of saralasin in hypertensive patients on chronic hemodialysis. Ann Intern Med. 1978; 88: 23-27.
12. Fadem SZ, Lifschitz MD. Use of saralasin in endstage renal disease. Kidney Int Suppl. 1979; 15: S93-S100.
13. Epstein M, Sancho J, Perez G, Haber E, Re R, Loutzenhiser R. Volume as a determinant of plasma aldosterone in anephric man. J Clin Endocri nol Metab. 1978; 46: 309-316.
14. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligoanuric hemodialysis patients. Am J Kidney Dis. 2005; 46: 94-101.
15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.
16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321.
17. Ritz E. How little aldosterone is able to raise blood pressure? Clin J Am Soc Nephrol. 2009; 4: 703-710.
18. Oberleithner H, Riethmüller C, Schillers H, Mac-Gregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA. 2007; 104: 16281-16286.
19. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101: 594-597.
20. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004; 109: 2857-2861.
21. Hayes CP, McLeod ME, Robinson RR. An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Phys, 1967; 80: 207-216.
22. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006; 119: 912-919.
23. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin PY. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant. 2003; 18: 2359-2363.
24. Covic A, Gusbeth-Tatomir P, Goldsmith DJA. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant. 2006; 21: 854-858.
25. Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent--novel functions for an old hormone. Nephrol Dial Transplant. 2009; 24: 2302-2305.
26. Taheri S, Mortazavi M, Shahidi S, Pourmoghadas A, Garakyaraghi M, Seirafian S, Eshaghian A, Ghassami M. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl. 2009; 20: 392-397.
27. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H, Shio N. Long-Term Low-Dose Spironolactone Therapy Is Safe in Oligoanuric Hemodialysis Patients Cardiology. 2009; 114: 32-38.
28. Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol. 2010; 33: 604-608.